CYBA作为肾细胞癌的潜在生物标志物:来自一项综合遗传分析的证据。
CYBA as a Potential Biomarker for Renal Cell Carcinoma: Evidence from an Integrated Genetic Analysis.
发表日期:2023
作者:
Chi-Fen Chang, Shu-Pin Huang, Yu-Mei Hsueh, Pei-Ling Chen, Cheng-Hsueh Lee, Jiun-Hung Geng, Chao-Yuan Huang, Bo-Ying Bao
来源:
GENOMICS PROTEOMICS & BIOINFORMATICS
摘要:
氧化应激在各种致病过程中起重要作用,NADPH氧化酶(NOX)产生的活性氧自由基协调产生的紊乱与癌变有关。然而,关于NOX基因中的遗传变异是否会对肾细胞癌(RCC)的发展起作用,目前还知之甚少。本研究旨在分析噬菌细胞NOX基因CYBA和CYBB中10个单核苷酸多态性与630例RCC患者和对照组的风险以及肿瘤特征的关联,以填补这一知识空白。利用从公共数据库中获取的基因表达数据进行差异基因表达和患者预后分析。多元分析和多重检验校正结果显示,与G等位基因相比,CYBA中rs7195830的A等位基因是RCC的显著性风险等位基因(奥赛比=1.70,95%置信区间=1.27-2.26,p<0.001)。对17个肾癌基因表达数据集的合并分析显示,在RCC中CYBA的表达量较正常组织高。此外,CYBA高表达与进展期肿瘤特征和患者预后恶化相关。CYBA可能在RCC中发挥致瘤作用,并作为预后评估指标。版权所有©2023年,国际抗癌研究学院(Dr. George J. Delinasios),保留所有权利。
Oxidative stress plays an important role in various pathogenic processes, and disruption in the coordinated production of NADPH oxidase (NOX)-derived reactive oxygen species has been associated with carcinogenesis. However, little is known about whether genetic variants in NOX can contribute to the development of renal cell carcinoma (RCC).This study aimed to bridge this knowledge gap by analysing the association of 10 single-nucleotide polymorphisms in the phagocyte NOX genes, CYBA and CYBB, with RCC risk and tumour characteristics in 630 RCC patients and controls. Differential gene expression and patient prognosis analyses were performed using gene expression data obtained from public databases.Multivariate analysis and multiple testing corrections revealed the A allele of rs7195830 in CYBA to be a significant risk allele for RCC, compared to the G allele [odds ratio (OR)=1.70, 95% confidence interval (CI)=1.27-2.26, p<0.001]. A pooled analysis of 17 renal cancer gene expression datasets revealed a higher CYBA expression in RCC than in normal tissues. Moreover, high CYBA expression was associated with advanced tumour characteristics and worse patient prognosis.CYBA might play an oncogenic role in RCC and serve as a predictive indicator of patient prognosis.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.